Open Label, Randomized, Multicentric Study To Establish Safety And Efficacy Of Recombinant Insulin Glargine Manufactured By Biocon Ltd Compared To LantusTM In Type 1 Diabetes Mellitus Patients.

Trial Profile

Open Label, Randomized, Multicentric Study To Establish Safety And Efficacy Of Recombinant Insulin Glargine Manufactured By Biocon Ltd Compared To LantusTM In Type 1 Diabetes Mellitus Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Insulin glargine (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Biocon
  • Most Recent Events

    • 01 Jul 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top